secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001493152-25-028850
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology raises $4.3M in registered direct offering; terminates royalty agreement
--------------------------------------------------------------------------------

- Gross proceeds ~$4.3M from 1,051,342 Common Units at $4.09/unit; each unit includes one share (or Pre-Funded Warrant) and one Common Warrant (exercise $3.96, 60-month term).
- Offering priced at market under Nasdaq rules; expected close Dec 19, 2025.
- Terminated Royalty Agreement with Orbit Capital Inc. (dated Nov 24, 2025); both parties released from claims.
- Net proceeds to be used for general corporate purposes and working capital.
- Spartan Capital Securities acted as sole placement agent with 6% fee and $85K legal expense reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225028850/0001493152-25-028850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225028850/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-028850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer